Trials of aliskiren for CAD and otamixaban for NSTE-ACS, chronic care management for substance dependence, and more.

Published: Sept. 17, 2013, 8 p.m.

Editor's Audio Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor, the Journal of the American Medical Association, for the September 18, 2013 issue